PHARMACEUTICALS
WATCH NOW
Training Surgical Robots with NVIDIA Isaac for Healthcare
Jensen Huang Chief Executive Officer NVIDIA
N
VIDIA is building the infrastructural backbone powering pharma’ s AI-native future. Its AI infrastructure, software platforms and foundation models are enabling everything from drug discovery and clinical development to smart manufacturing and enterprise-wide generative AI. Partnerships with pharma’ s biggest players, including providing the infrastructure behind the purported“ most powerful AI factory in life sciences” with Bristol Myers Squibb, its suite of industry-specific platforms, such as BioNeMo and Isaac For Healthcare, as well as providing open-source robotics simulators to accelerate medical robotics development, all place the company at the centre of the industry’ s next digital revolution. To provide a sense of NVIDIA’ s vast healthcare exposure, its portfolio now spans, but is not limited to:
• BioNeMo – a platform of foundation models for protein structure prediction, molecular generation and drug discovery.
• DGX SuperPOD – AI supercomputing infrastructure used by pharmaceutical companies to train large biological models.
• NVIDIA AI Enterprise – software for deploying generative AI securely across regulated environments.
• Omniverse – digital twin technology for manufacturing facilities and laboratories.
• Clara – AI platform supporting medical imaging, genomics and computational healthcare.
Discussing the role of computing in pharmaceutical research, Jensen Huang, CEO of NVIDIA, says:“ I can’ t imagine a more worthy field to apply computer science to. Hopefully we can bend the arc of history.”
healthcare-digital. com 85